Search

Your search keyword '"De Falco, Filomena"' showing total 26 results
Start Over Author "De Falco, Filomena"
26 results on '"De Falco, Filomena"'

1. A pro-inflammatory environment in bone marrow of Treg transplanted patients matches with graft-versus-leukemia effect

Author

Guardalupi, Francesco, Sorrentino, Carlo, Corradi, Giulia, Giancola, Raffaella, Baldoni, Stefano, Ulbar, Francesca, Fabi, Bianca, Andres Ejarque, Rosa, Timms, Jessica, Restuccia, Francesco, Santarone, Stella, Accorsi, Patrizia, Sportoletti, Paolo, De Falco, Filomena, Rosati, Emanuela, Carotti, Alessandra, Falzetti, Franca, Velardi, Andrea, Martelli, Massimo Fabrizio, Kordasti, Shahram, Pierini, Antonio, Ruggeri, Loredana, and Di Ianni, Mauro

Published
2023
Full Text
View/download PDF

3. NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models

Author

Baldoni, Stefano, Ruggeri, Loredana, Del Papa, Beatrice, Sorcini, Daniele, Guardalupi, Francesco, Ulbar, Francesca, Marra, Andrea, Dorillo, Erica, Stella, Arianna, Giancola, Raffaella, Fabi, Bianca, Sola, Rosaria, Ciardelli, Sara, De Falco, Filomena, Rompietti, Chiara, Adamo, Francesco Maria, Rosati, Emanuela, Pierini, Antonio, Sorrentino, Carlo, Sportoletti, Paolo, and Di Ianni, Mauro

Published
2021
Full Text
View/download PDF

4. Nanotechnology Advances in the Detection and Treatment of Lymphoid Malignancies.

Author

Adamo, Francesco Maria, De Falco, Filomena, Dorillo, Erica, Sorcini, Daniele, Stella, Arianna, Esposito, Angela, Arcaleni, Roberta, Rosati, Emanuela, and Sportoletti, Paolo

Subjects
*DISEASE management, *INDIVIDUALIZED medicine, *HEMATOLOGIC malignancies, *SYMPTOMS, *NANOTECHNOLOGY
Abstract

Lymphoid malignancies are complex diseases with distinct biological behaviors, clinical presentations, and treatment responses. Ongoing research and advancements in biotechnology enhance the understanding and management of these malignancies, moving towards more personalized approaches for diagnosis and treatment. Nanotechnology has emerged as a promising tool to improve some limitations of conventional diagnostics as well as treatment strategies for lymphoid malignancies. Nanoparticles (NPs) offer unique advantages such as enhanced multimodal detection, drug delivery, and targeted therapy capabilities, with the potential to improve precision medicine and patient outcomes. Here, we comprehensively examine the current landscape of nanoconstructs applied in the management of lymphoid disease. Through a comprehensive analysis of preclinical studies, we highlight the translational potential of NPs in revolutionizing the field of hematological malignancies, with a specific focus on lymphoid neoplasms. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential

Author

Silva Barcelos, Estevão Carlos, primary, Rompietti, Chiara, additional, Adamo, Francesco Maria, additional, Dorillo, Erica, additional, De Falco, Filomena, additional, Del Papa, Beatrice, additional, Baldoni, Stefano, additional, Nogarotto, Manuel, additional, Esposito, Angela, additional, Capoccia, Silvia, additional, Geraci, Clelia, additional, Sorcini, Daniele, additional, Stella, Arianna, additional, Arcaleni, Roberta, additional, Tini, Valentina, additional, Imbroisi Valle Errera, Flávia, additional, Rosati, Emanuela, additional, and Sportoletti, Paolo, additional

Published
2023
Full Text
View/download PDF

7. Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia

Author

Adamo, Francesco Maria, primary, Silva Barcelos, Estevao Carlos, additional, De Falco, Filomena, additional, Dorillo, Erica, additional, Rompietti, Chiara, additional, Sorcini, Daniele, additional, Stella, Arianna, additional, Del Papa, Beatrice, additional, Baldoni, Stefano, additional, Esposito, Angela, additional, Geraci, Clelia, additional, Arcaleni, Roberta, additional, Pennetta, Chiara, additional, Ragonese, Francesco, additional, Moretti, Lorenzo, additional, Mameli, Mariagrazia, additional, Di Ianni, Mauro, additional, Rosati, Emanuela, additional, Fioretti, Bernard, additional, and Sportoletti, Paolo, additional

Published
2023
Full Text
View/download PDF

8. Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

Author

Mauro, Francesca R., primary, Giannarelli, Diana, additional, Galluzzo, Clementina M., additional, Visentin, Andrea, additional, Frustaci, Anna M., additional, Sportoletti, Paolo, additional, Vitale, Candida, additional, Reda, Gianluigi, additional, Gentile, Massimo, additional, Levato, Luciano, additional, Murru, Roberta, additional, Armiento, Daniele, additional, Molinari, Maria C., additional, Proietti, Giulia, additional, Pepe, Sara, additional, De Falco, Filomena, additional, Mattiello, Veronica, additional, Barabino, Luca, additional, Amici, Roberta, additional, Coscia, Marta, additional, Tedeschi, Alessandra, additional, Girmenia, Corrado, additional, Trentin, Livio, additional, and Baroncelli, Silvia, additional

Published
2023
Full Text
View/download PDF

9. Figure S10 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia

Author

Del Papa, Beatrice, primary, Baldoni, Stefano, primary, Dorillo, Erica, primary, De Falco, Filomena, primary, Rompietti, Chiara, primary, Cecchini, Debora, primary, Cantelmi, Maria Grazia, primary, Sorcini, Daniele, primary, Nogarotto, Manuel, primary, Adamo, Francesco Maria, primary, Mezzasoma, Federica, primary, Silva Barcelos, Estevão Carlos, primary, Albi, Elisa, primary, Iacucci Ostini, Roberta, primary, Di Tommaso, Ambra, primary, Marra, Andrea, primary, Montanaro, Guido, primary, Martelli, Maria Paola, primary, Falzetti, Franca, primary, Di Ianni, Mauro, primary, Rosati, Emanuela, primary, and Sportoletti, Paolo, primary

Published
2023
Full Text
View/download PDF

10. Immune correlates of protection by vaccine against SARS‐CoV ‐2 in patients with chronic lymphocytic leukaemia

Author

Sorcini, Daniele, primary, De Falco, Filomena, additional, Gargaro, Marco, additional, Bozza, Silvia, additional, Guarente, Valerio, additional, Cardinali, Valeria, additional, Stella, Arianna, additional, Adamo, Francesco Maria, additional, Silva Barcelos, Estevao Carlos, additional, Rompietti, Chiara, additional, Dorillo, Erica, additional, Geraci, Clelia, additional, Esposito, Angela, additional, Arcaleni, Roberta, additional, Capoccia, Silvia, additional, Mameli, Maria Grazia, additional, Graziani, Alessandro, additional, Moretti, Lorenzo, additional, Cipiciani, Alessandra, additional, Riccardi, Carlo, additional, Mencacci, Antonella, additional, Fallarino, Francesca, additional, Rosati, Emanuela, additional, and Sportoletti, Paolo, additional

Published
2022
Full Text
View/download PDF

11. NOTCH1-mutated chronic lymphocytic leukemia displays high endoplasmic reticulum stress response with druggable potential.

Author

Barcelos, Estevão Carlos Silva, Rompietti, Chiara, Adamo, Francesco Maria, Dorillo, Erica, De Falco, Filomena, Del Papa, Beatrice, Baldoni, Stefano, Nogarotto, Manuel, Esposito, Angela, Capoccia, Silvia, Geraci, Clelia, Sorcini, Daniele, Stella, Arianna, Arcaleni, Roberta, Tini, Valentina, Valle Errera, Flávia Imbroisi, Rosati, Emanuela, and Sportoletti, Paolo

Subjects
CHRONIC lymphocytic leukemia, CHRONIC leukemia, ENDOPLASMIC reticulum, GENE ontology, UNFOLDED protein response, POLYMERASE chain reaction, B cells
Abstract

Introduction: Constitutive activation of NOTCH1-wild-type (NT1-WT) signaling is associated with poor outcomes in chronic lymphocytic leukemia (CLL), and NOTCH1 mutation (c.7541_7542delCT), which potentiates NOTCH1 signaling, worsens the prognosis. However, the specific mechanisms of NOTCH1 deregulation are still poorly understood. Accumulative evidence mentioned endoplasmic reticulum (ER) stress/unfolded protein response (UPR) as a key targetable pathway in CLL. In this study, we investigated the impact of NOTCH1 deregulation on CLL cell response to ER stress induction, with the aim of identifying new therapeutic opportunities for CLL. Methods: We performed a bioinformatics analysis of NOTCH1-mutated (NT1-M) and NT1-WT CLL to identify differentially expressed genes (DEGs) using the rank product test. Quantitative real-time polymerase chain reaction (qPCR), Western blotting, cytosolic Ca2+, and annexin V/propidium iodide (PI) assay were used to detect curcumin ER stress induction effects. A median-effect equation was used for drug combination tests. The experimental mouse model E -TCL1 was used to evaluate the impact of ER stress exacerbation by curcumin treatment on the progression of leukemic cells and NOTCH1 signaling. Results and discussion: Bioinformatics analysis revealed gene enrichment of the components of the ER stress/UPR pathway in NT1-M compared to those in NT1- WT CLL. Ectopic expression of NOTCH1 mutation upregulated the levels of ER stress response markers in the PGA1 CLL cell line. Primary NT1-M CLL was more sensitive to curcumin as documented by a significant perturbation in Ca2+ homeostasis and higher expression of ER stress/UPR markers compared to NT1-WT cells. It was also accompanied by a significantly higher apoptotic response mediated by C/EBP homologous protein (CHOP) expression, caspase 4 cleavage, and downregulation of NOTCH1 signaling in NT1-M CLL cells. Curcumin potentiated the apoptotic effect of venetoclax in NT1-M CLL cells. In E -TCL1 leukemic mice, the administration of curcumin activated ER stress in splenic B cells ex vivo and significantly reduced the percentage of CD19+/CD5+ cells infiltrating the spleen, liver, and bone marrow (BM). These cellular effects were associated with reduced NOTCH1 activity in leukemic cells and resulted in prolonged survival of curcumin-treated mice. Overall, our results indicate that ER stress induction in NT1-M CLL might represent a new therapeutic opportunity for these high-risk CLL patients and improve the therapeutic effect of drugs currently used in CLL. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Immune correlates of protection by vaccine against SARS‐CoV‐2 in patients with chronic lymphocytic leukaemia.

Author

Sorcini, Daniele, De Falco, Filomena, Gargaro, Marco, Bozza, Silvia, Guarente, Valerio, Cardinali, Valeria, Stella, Arianna, Adamo, Francesco Maria, Silva Barcelos, Estevao Carlos, Rompietti, Chiara, Dorillo, Erica, Geraci, Clelia, Esposito, Angela, Arcaleni, Roberta, Capoccia, Silvia, Mameli, Maria Grazia, Graziani, Alessandro, Moretti, Lorenzo, Cipiciani, Alessandra, and Riccardi, Carlo

Subjects
*LYMPHOCYTIC leukemia, *CHRONIC leukemia, *COVID-19 vaccines, *BRUTON tyrosine kinase, *INTERFERON gamma
Abstract

Summary: In chronic lymphocytic leukaemia (CLL) the efficacy of SARS‐CoV‐2 vaccination remains unclear as most studies have focused on humoral responses. Here we comprehensively examined humoral and cellular responses to vaccine in CLL patients. Seroconversion was observed in 55.2% of CLL with lower rate and antibody titres in treated patients. T‐cell responses were detected in a significant fraction of patients. CD4+ and CD8+ frequencies were significantly increased independent of serology with higher levels of CD4+ cells in patients under a Bruton tyrosine kinase (BTK) or a B‐cell lymphoma 2 (BCL‐2) inhibitor. Vaccination skewed CD8+ cells towards a highly cytotoxic phenotype, more pronounced in seroconverted patients. A high proportion of patients showed spike‐specific CD4+ and CD8+ cells producing interferon gamma (IFNγ) and tumour necrosis factor alpha (TNFα). Patients under a BTK inhibitor showed increased production of IFNγ and TNFα by CD4+ cells. Vaccination induced a Th1 polarization reverting the Th2 CLL T‐cell profile in the majority of patients with lower IL‐4 production in untreated and BTK‐inhibitor‐treated patients. Such robust T‐cell responses may have contributed to remarkable protection against hospitalization and death in a cohort of 540 patients. Combining T‐cell metrics with seroprevalence may yield a more accurate measure of population immunity in CLL, providing consequential insights for public health. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia

Author

Guarente, Valerio, primary, Martino, Giovanni, additional, Dorillo, Erica, additional, De Falco, Filomena, additional, Rompietti, Chiara, additional, Sorcini, Daniele, additional, Brogna, Mariangela, additional, Cardinali, Valeria, additional, Ascani, Stefano, additional, Marra, Andrea, additional, and Sportoletti, Paolo, additional

Published
2021
Full Text
View/download PDF

16. NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications

Author

Sportoletti, Paolo, primary, De Falco, Filomena, additional, Del Papa, Beatrice, additional, Baldoni, Stefano, additional, Guarente, Valerio, additional, Marra, Andrea, additional, Dorillo, Erica, additional, Rompietti, Chiara, additional, Adamo, Francesco Maria, additional, Ruggeri, Loredana, additional, Di Ianni, Mauro, additional, and Rosati, Emanuela, additional

Published
2021
Full Text
View/download PDF

17. Bepridil exhibits anti‐leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia

Author

Baldoni, Stefano, Del Papa, Beatrice, Dorillo, Erica, Aureli, Patrizia, De Falco, Filomena, Rompietti, Chiara, Sorcini, Daniele, Varasano, Emanuela, Cecchini, Debora, Zei, Tiziana, Di Tommaso, Ambra, Rosati, Emanuela, Alexe, Gabriela, Roti, Giovanni, Stegmaier, Kimberly, Di Ianni, Mauro, Falzetti, Franca, and Sportoletti, Paolo

Subjects
Bepridil, Antineoplastic Agents, Apoptosis, Mice, NOTCH1, hemic and lymphatic diseases, Biomarkers, Tumor, Tumor Microenvironment, Animals, Humans, Receptor, Notch1, Cancer Therapy and Prevention, Chemotaxis, Mesenchymal Stem Cells, targeted therapy, Calcium Channel Blockers, Prognosis, Leukemia, Lymphocytic, Chronic, B-Cell, Xenograft Model Antitumor Assays, embryonic structures, Mutation, cardiovascular system, chronic lymphocytic leukemia, sense organs, biological phenomena, cell phenomena, and immunity, Drug Screening Assays, Antitumor
Abstract

Dysregulated NOTCH1 signaling, by either gene mutations or microenvironment interactions, has been increasingly linked to chronic lymphocytic leukemia (CLL). Thus, inhibiting NOTCH1 activity represents a potential therapeutic opportunity for this disease. Using gene expression‐based screening, we identified the calcium channel modulator bepridil as a new NOTCH1 pathway inhibitor. In primary CLL cells, bepridil induced selective apoptosis even in the presence of the protective stroma. Cytotoxic effects of bepridil were independent of NOTCH1 mutation and other prognostic markers. The antitumor efficacy of bepridil was associated with inhibition of NOTCH1 activity through a decrement in trans‐membrane and activated NOTCH1 protein levels with unchanged NOTCH2 protein levels. In a CLL xenotransplant model, bepridil significantly reduced the percentage of leukemic cells infiltrating the spleen via enhanced apoptosis and decreased NOTCH1 activation. In conclusion, we report in vitro and in vivo anti‐leukemic activity of bepridil associated with inhibition of the NOTCH1 pathway in CLL. These data provide a rationale for the clinical development of bepridil as anti‐NOTCH1 targeted therapy for CLL patients., What's new? In search of new inroads against chronic lymphocytic leukemia, these authors turned to the NOTCH1 signalling pathway. Could inhibiting NOTCH1 help treat CLL? To find out, they first identified the calcium channel blocker bepridil as a NOTCH1 inhibitor. Next, they showed that bepredil induced apoptosis in isolated CLL cells, regardless of whether they bore NOTCH1 mutations. In mice bearing CLL cells, bepredil inhibited the proliferation of the tumor cells with no overt signs of toxicity. Thus, it seems advisable to pursue bepredil as a possible candidate for treating CLL.

Published
2018

18. NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status

Author

Baldoni, Stefano, primary, Del Papa, Beatrice, additional, De Falco, Filomena, additional, Dorillo, Erica, additional, Sorrentino, Carlo, additional, Rompietti, Chiara, additional, Adamo, Francesco Maria, additional, Nogarotto, Manuel, additional, Cecchini, Debora, additional, Mondani, Elena, additional, Silva Barcelos, Estevao Carlos, additional, Moretti, Lorenzo, additional, Mameli, Maria Grazia, additional, Fabi, Bianca, additional, Sorcini, Daniele, additional, Stella, Arianna, additional, Giancola, Raffaella, additional, Guardalupi, Francesco, additional, Ulbar, Francesca, additional, Plebani, Sara, additional, Guarente, Valerio, additional, Rosati, Emanuela, additional, Di Nicola, Marta, additional, Marchioni, Michele, additional, Di Ianni, Mauro, additional, and Sportoletti, Paolo, additional

Published
2021
Full Text
View/download PDF

20. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia

Author

Del Papa, Beatrice, primary, Baldoni, Stefano, additional, Dorillo, Erica, additional, De Falco, Filomena, additional, Rompietti, Chiara, additional, Cecchini, Debora, additional, Cantelmi, Maria Grazia, additional, Sorcini, Daniele, additional, Nogarotto, Manuel, additional, Adamo, Francesco Maria, additional, Mezzasoma, Federica, additional, Silva Barcelos, Estevão Carlos, additional, Albi, Elisa, additional, Iacucci Ostini, Roberta, additional, Di Tommaso, Ambra, additional, Marra, Andrea, additional, Montanaro, Guido, additional, Martelli, Maria Paola, additional, Falzetti, Franca, additional, Di Ianni, Mauro, additional, Rosati, Emanuela, additional, and Sportoletti, Paolo, additional

Published
2019
Full Text
View/download PDF

21. NOTCH1 Aberrations in Chronic Lymphocytic Leukemia

Author

Rosati, Emanuela, primary, Baldoni, Stefano, additional, De Falco, Filomena, additional, Del Papa, Beatrice, additional, Dorillo, Erica, additional, Rompietti, Chiara, additional, Albi, Elisa, additional, Falzetti, Franca, additional, Di Ianni, Mauro, additional, and Sportoletti, Paolo, additional

Published
2018
Full Text
View/download PDF

22. NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells

Author

Di Ianni, Mauro, primary, Baldoni, Stefano, additional, Del Papa, Beatrice, additional, Aureli, Patrizia, additional, Dorillo, Erica, additional, De Falco, Filomena, additional, Albi, Elisa, additional, Varasano, Emanuela, additional, Di Tommaso, Ambra, additional, Giancola, Raffaella, additional, Accorsi, Patrizia, additional, Rotta, Gianluca, additional, Rompietti, Chiara, additional, Silva Barcelos, Estevão Carlos, additional, Campese, Antonio Francesco, additional, Di Bartolomeo, Paolo, additional, Screpanti, Isabella, additional, Rosati, Emanuela, additional, Falzetti, Franca, additional, and Sportoletti, Paolo, additional

Published
2018
Full Text
View/download PDF

25. γ‐Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down‐regulation

Author

Rosati, Emanuela, primary, Sabatini, Rita, additional, De Falco, Filomena, additional, Del Papa, Beatrice, additional, Falzetti, Franca, additional, Di Ianni, Mauro, additional, Cavalli, Laura, additional, Fettucciari, Katia, additional, Bartoli, Andrea, additional, Screpanti, Isabella, additional, and Marconi, Pierfrancesco, additional

Published
2012
Full Text
View/download PDF

26. Cocaine Addiction Treatment and Home Remedies: Use of the Scopolamine Transdermal Patch.

Author

Gambelunghe, Cristiana, Bacci, Mauro, Aroni, Kyriaki, De Falco, Filomena, and Ayroldi, Emira Maria

Subjects
DRUG withdrawal symptoms, COCAINE, DRUG addiction, GAS chromatography, MASS spectrometry, QUESTIONNAIRES, SCOPOLAMINE, TRANSDERMAL medication, HAIR analysis, DESCRIPTIVE statistics, PREVENTION, THERAPEUTICS
Abstract

Recently, there has been an enormous increase in the number of people seeking treatment for cocaine addiction. Fifteen male cocaine users aged 20-30 years who requested hair analysis from our forensic toxicology laboratory (Perugia, Italy) from March to June 2012, reported using scopolamine without medical supervision to reduce the anxiety associated with cocaine withdrawal. Self-reports were verified with the results obtained from the hair analysis. We discuss whether the use of scopolamine in cocaine abusers could be supported by a neurobiological and pharmacological point of view. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results